Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 7,138 shares of Hologic stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Lawrence M. Levy also recently made the following trade(s):

  • On Thursday, September 7th, Lawrence M. Levy sold 7,139 shares of Hologic stock. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56.

Shares of Hologic, Inc. (NASDAQ HOLX) traded down 0.08% on Tuesday, hitting $36.86. 2,428,699 shares of the stock were exchanged. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market cap of $10.34 billion, a PE ratio of 13.73 and a beta of 0.91. The company’s 50 day moving average is $37.75 and its 200-day moving average is $42.06.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same period in the prior year, the firm earned $0.51 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Hologic, Inc. (HOLX) Director Sells $266,818.44 in Stock” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/10/hologic-inc-holx-director-sells-266818-44-in-stock.html.

Several hedge funds have recently added to or reduced their stakes in HOLX. Neuberger Berman Group LLC increased its stake in shares of Hologic by 1,735.5% during the first quarter. Neuberger Berman Group LLC now owns 289,874 shares of the medical equipment provider’s stock worth $12,334,000 after buying an additional 274,081 shares during the period. OppenheimerFunds Inc. increased its stake in shares of Hologic by 31.5% during the first quarter. OppenheimerFunds Inc. now owns 377,892 shares of the medical equipment provider’s stock worth $16,080,000 after buying an additional 90,435 shares during the period. Principal Financial Group Inc. increased its stake in shares of Hologic by 1.3% during the first quarter. Principal Financial Group Inc. now owns 432,748 shares of the medical equipment provider’s stock worth $18,413,000 after buying an additional 5,669 shares during the period. Teachers Advisors LLC increased its stake in shares of Hologic by 36.4% during the first quarter. Teachers Advisors LLC now owns 877,549 shares of the medical equipment provider’s stock worth $37,340,000 after buying an additional 234,002 shares during the period. Finally, Investec Asset Management LTD increased its stake in shares of Hologic by 0.3% during the first quarter. Investec Asset Management LTD now owns 1,706,642 shares of the medical equipment provider’s stock worth $72,618,000 after buying an additional 5,294 shares during the period. Hedge funds and other institutional investors own 96.38% of the company’s stock.

HOLX has been the topic of a number of research reports. Royal Bank Of Canada cut their target price on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC cut their target price on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $47.77.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.